In addition to the role of p53 in cell cycle arrest and apoptosis, a growing body of evidence suggests that activation of p53 in the tumor microenvironment following MDM2i treatment could result in stromal senescence and an immunosuppressive microenvironment 13, 14, 15. The gene discussed is TP53; the disease is neoplasm.